US-guided microwave ablation for primary hyperparathyroidism: a safety and efficacy study

Objectives To evaluate the safety and efficacy of microwave ablation (MWA) with the assistance of continuous cool saline injection (CCSI) in patients with primary hyperparathyroidism (PHPT). Methods Between November 1, 2014, and February 29, 2016, 22 patients with PHPT were enrolled and treated with...

Full description

Saved in:
Bibliographic Details
Published in:European radiology 2019-10, Vol.29 (10), p.5607-5616
Main Authors: Fan, Bo-qiang, He, Xiao-wei, Chen, Huan-huan, Zhang, Wei-ming, Tang, Wei
Format: Article
Language:English
Subjects:
Ablation
Adult
Aged
Aged, 80 and over
Calcium
Calcium (blood)
Diagnostic Radiology
Diathermy - methods
Dietary supplements
Effectiveness
Female
Head and Neck
Humans
Hypercalcemia
Hyperparathyroidism
Hyperparathyroidism, Primary - diagnosis
Hyperparathyroidism, Primary - therapy
Hypocalcemia
Imaging
Internal Medicine
Interventional Radiology
Male
Medicine
Medicine & Public Health
Microwave ablation
Microwaves - therapeutic use
Middle Aged
Neuroradiology
Parathyroid
Parathyroid gland
Parathyroid hormone
Patients
Radiology
Safety
Side effects
Treatment Outcome
Ultrasonography, Interventional - methods
Ultrasound
Variance analysis
Vitamin D
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To evaluate the safety and efficacy of microwave ablation (MWA) with the assistance of continuous cool saline injection (CCSI) in patients with primary hyperparathyroidism (PHPT). Methods Between November 1, 2014, and February 29, 2016, 22 patients with PHPT were enrolled and treated with ultrasound-guided MWA assisted by CCSI. The levels of parathyroid hormone (PTH) and serum calcium were recorded before and after the MWA. Patients were divided into two groups (normalized and unnormalized groups) according to treatment efficacy. Fisher’s exact test and the Mann-Whitney test were used to compare data between the two groups. Timing differences in serum PTH and calcium levels were analyzed with repeated measures analysis of variance. Results Normalized outcomes for both PTH and calcium levels were achieved in 19 of 22 (86.36%) patients with PHPT. In the normalized group, PTH levels remained normal for 12 months after MWA. PTH levels in the unnormalized group were outside the reference range at six of seven follow-ups within 12 months following MWA. By contrast, serum calcium levels gradually decreased in all patients in both groups. The mean serum PTH and mean calcium levels at 6 months after therapy were significantly lower than those before MWA (both p  
ISSN:0938-7994
1432-1084
DOI:10.1007/s00330-019-06078-y